{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:44:33Z","timestamp":1785350673192,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40618-019-01161-z","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T17:03:47Z","timestamp":1576256627000},"page":"767-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Systemic safety analysis of mycophenolate in Graves\u2019 orbitopathy"],"prefix":"10.1007","volume":"43","author":[{"given":"A. C. H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-430X","authenticated-orcid":false,"given":"G. J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"issue":"8","key":"1161_CR1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","volume":"37","author":"L Bartalena","year":"2014","unstructured":"Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update. J Endocrinol Invest 37(8):691\u2013700","journal-title":"J Endocrinol Invest"},{"key":"1161_CR2","first-page":"15","volume":"19","author":"YP Hai","year":"2019","unstructured":"Hai YP, Lee ACH, Frommer L, Diana T, Kahaly GJ (2019) Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy. J Endocrinol Invest 19:15","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1161_CR3","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century. J Endocrinol Invest 36(6):444\u2013449","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1161_CR4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40618-015-0257-z","volume":"38","author":"L Bartalena","year":"2015","unstructured":"Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves\u2019 hyperthyroidism on Graves\u2019 orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest 38(4):481\u2013487","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1161_CR5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","volume":"88","author":"CE Staatz","year":"2014","unstructured":"Staatz CE, Tett SE (2014) Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 88(7):1351\u20131389","journal-title":"Arch Toxicol"},{"issue":"2\u20133","key":"1161_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2\u20133):85\u2013118","journal-title":"Immunopharmacology"},{"key":"1161_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1993.tb35881.x","volume":"685","author":"EM Eugui","year":"1993","unstructured":"Eugui EM, Allison AC (1993) Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 685:309\u2013329","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"1161_CR8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/14740338.2010.513379","volume":"9","author":"K Budde","year":"2010","unstructured":"Budde K, Durr M, Liefeldt L, Neumayer HH, Glander P (2010) Enteric-coated mycophenolate sodium. Expert Opin Drug Saf 9(6):981\u2013994","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1161_CR9","first-page":"125","volume":"43","author":"J Wang","year":"2004","unstructured":"Wang J, Wang YT, Shao JQ, Wang X, Du H (2004) Immunosuppressive therapies in patients with Graves\u2019 ophthalmopathy. Zhonghua Nei Ke Za Zhi 43(2):125\u2013127","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"6","key":"1161_CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40618-016-0441-9","volume":"39","author":"M Riedl","year":"2016","unstructured":"Riedl M, Kuhn A, Kramer I, Kolbe E, Kahaly GJ (2016) Prospective, systematically recorded mycophenolate safety data in Graves\u2019 orbitopathy. J Endocrinol Invest 39(6):687\u2013694","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1161_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"Ye X, Bo X, Hu X, Cui H, Lu B, Shao J et al (2017) Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin Endocrinol (Oxf) 86(2):247\u2013255","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1161_CR12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K, Diana T et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6(4):287\u2013298","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1161_CR13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL et al (2016) 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343\u20131421","journal-title":"Thyroid"},{"issue":"5","key":"1161_CR14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.eye.6701925","volume":"20","author":"CC Tsai","year":"2006","unstructured":"Tsai CC, Kau HC, Kao SC, Hsu WM (2006) Exophthalmos of patients with Graves\u2019 disease in Chinese of Taiwan. Eye (Lond) 20(5):569\u2013573","journal-title":"Eye (Lond)"},{"issue":"9","key":"1161_CR15","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archinte.1980.00330200106028","volume":"140","author":"E de Juan Jr","year":"1980","unstructured":"de Juan E Jr., Hurley DP, Sapira JD (1980) Racial differences in normal values of proptosis. Arch Intern Med 140(9):1230\u20131231","journal-title":"Arch Intern Med"},{"issue":"6","key":"1161_CR16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/thy.2000.10.521","volume":"10","author":"M Weissel","year":"2000","unstructured":"Weissel M, Hauff W (2000) Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 10(6):521","journal-title":"Thyroid"},{"issue":"5","key":"1161_CR17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","volume":"14","author":"M Marino","year":"2004","unstructured":"Marino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy. Thyroid 14(5):403\u2013406","journal-title":"Thyroid"},{"issue":"8","key":"1161_CR18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/1050725041692927","volume":"14","author":"M Salvi","year":"2004","unstructured":"Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S et al (2004) Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto\u2019s thyroiditis: case report. Thyroid 14(8):631\u2013634","journal-title":"Thyroid"},{"issue":"1","key":"1161_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12020-016-0928-3","volume":"54","author":"M Moleti","year":"2016","unstructured":"Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campenni A, Morelli S et al (2016) Acute liver damage following intravenous glucocorticoid treatment for Graves\u2019 ophthalmopathy. Endocrine 54(1):259\u2013268","journal-title":"Endocrine"},{"issue":"2","key":"1161_CR20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ndt\/gfl539","volume":"22","author":"JP Rerolle","year":"2007","unstructured":"Rerolle JP, Szelag JC, Le Meur Y (2007) Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transplant 22(2):671\u2013672","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1161_CR21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5935\/0101-2800.20170014","volume":"39","author":"MM Mendes","year":"2017","unstructured":"Mendes MM, Carminatti M, Pinheiro HS (2017) Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient. J Bras Nefrol 39(1):82\u201385","journal-title":"J Bras Nefrol"},{"issue":"9","key":"1161_CR22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Mitjavila F, Castro Salomo A et al (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 76(9):1575\u20131582","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1161_CR23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","volume":"121","author":"SR Rathinam","year":"2014","unstructured":"Rathinam SR, Babu M, Thundikandy R, Kanakath A, Nardone N, Esterberg E et al (2014) A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology 121(10):1863\u20131870","journal-title":"Ophthalmology"},{"issue":"9","key":"1161_CR24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1161_CR25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69(6):788\u2013795","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1161_CR26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.kint.2018.07.021","volume":"94","author":"P Remy","year":"2018","unstructured":"Remy P, Audard V, Natella PA, Pelle G, Dussol B, Leray-Moragues H et al (2018) An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney Int 94(6):1217\u20131226","journal-title":"Kidney Int"},{"issue":"1","key":"1161_CR27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2019","unstructured":"Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxf) 58(1):52\u201360","journal-title":"Rheumatology (Oxf)"},{"issue":"7","key":"1161_CR28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","volume":"14","author":"J Tuin","year":"2019","unstructured":"Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW et al (2019) Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial. Clin J Am Soc Nephrol 14(7):1021\u20131028","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1161_CR29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","volume":"24","author":"HJ Eisen","year":"2005","unstructured":"Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R et al (2005) Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24(5):517\u2013525","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"1161_CR30","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ajt.13835","volume":"16","author":"M Strueber","year":"2016","unstructured":"Strueber M, Warnecke G, Fuge J, Simon AR, Zhang R, Welte T et al (2016) Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial. Am J Transplant 16(11):3171\u20133180","journal-title":"Am J Transplant"},{"issue":"5","key":"1161_CR31","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","volume":"17","author":"Y Qazi","year":"2017","unstructured":"Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR et al (2017) Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant 17(5):1358\u20131369","journal-title":"Am J Transplant"},{"issue":"6","key":"1161_CR32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1161_CR33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","volume":"129","author":"GB Bartley","year":"2011","unstructured":"Bartley GB (2011) Rundle and his curve. Arch Ophthalmol 129(3):356\u2013358","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1161_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C et al (2016) The 2016 European thyroid association\/european group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J. 5(1):9\u201326","journal-title":"Eur Thyroid J."},{"issue":"4","key":"1161_CR35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","volume":"38","author":"P Perros","year":"1993","unstructured":"Perros P, Crombie AL, Matthews JN, Kendall-Taylor P (1993) Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38(4):367\u2013372","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1161_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","volume":"79","author":"WM Wiersinga","year":"2013","unstructured":"Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79(2):145\u2013151","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1161_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","volume":"62","author":"CB Terwee","year":"2005","unstructured":"Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM (2005) Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 62(2):145\u2013155","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1161_CR38","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","volume":"95","author":"SD Lytton","year":"2010","unstructured":"Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ (2010) A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 95(5):2123\u20132131","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1161_CR39","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","volume":"118","author":"KA Ponto","year":"2011","unstructured":"Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ (2011) Clinical relevance of thyroid-stimulating immunoglobulins in Graves\u2019 ophthalmopathy. Ophthalmology 118(11):2279\u20132285","journal-title":"Ophthalmology"},{"issue":"7","key":"1161_CR40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40618-015-0254-2","volume":"38","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Diana T, Binder H, Matheis N, Pitz S, Pfeiffer N et al (2015) Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy. J Endocrinol Invest 38(7):769\u2013777","journal-title":"J Endocrinol Invest"},{"key":"1161_CR41","doi-asserted-by":"crossref","first-page":"678194","DOI":"10.1155\/2015\/678194","volume":"2015","author":"E Kampmann","year":"2015","unstructured":"Kampmann E, Diana T, Kanitz M, Hoppe D, Kahaly GJ (2015) Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study. Int J Endocrinol 2015:678194","journal-title":"Int J Endocrinol"},{"issue":"1","key":"1161_CR42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000375445","volume":"4","author":"GJ Kahaly","year":"2015","unstructured":"Kahaly GJ (2015) Bioassays for TSH receptor antibodies: quo vadis? Eur Thyroid J. 4(1):3\u20135","journal-title":"Eur Thyroid J."},{"issue":"5","key":"1161_CR43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000478522","volume":"6","author":"T Diana","year":"2017","unstructured":"Diana T, Wuster C, Olivo PD, Unterrainer A, Konig J, Kanitz M et al (2017) Performance and specificity of 6 immunoassays for TSH receptor antibodies: a multicenter study. Eur Thyroid J. 6(5):243\u2013249","journal-title":"Eur Thyroid J."},{"issue":"7","key":"1161_CR44","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1210\/jc.2018-02705","volume":"104","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ, Wuster C, Olivo PD, Diana T (2019) High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves disease. J Clin Endocrinol Metab 104(7):2561\u20132568","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01161-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:52:01Z","timestamp":1607734321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01161-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1161"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01161-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors stated that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}